Assembly Biosciences
ASMB
98 hedge funds and large institutions have $204M invested in Assembly Biosciences in 2019 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 32 increasing their positions, 37 reducing their positions, and 19 closing their positions.
4,252% more call options, than puts
Call options by funds: $5.48M | Put options by funds: $126K
0.16% less ownership
Funds ownership: 6.88% → 6.72% (-0.16%)
8% less funds holding
Funds holding: 106 → 98 (-8)
14% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 37
29% less capital invested
Capital invested by funds: $286M → $204M (-$82.3M)
42% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 19
Top Buyers
| 1 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$9.33M |
| 2 |
AC
Armistice Capital
New York
|
+$5.9M |
| 3 |
CCPM
Cooper Creek Partners Management
New York
|
+$3M |
| 4 |
D.E. Shaw & Co
New York
|
+$2.36M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.51M |
Top Sellers
| 1 |
O
OrbiMed
New York
|
-$7.06M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.54M |
| 3 |
Jennison Associates
New York
|
-$2.71M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$2.7M |
| 5 |
Millennium Management
New York
|
-$2.53M |
ASMB Hedge Fund Activity: Q3 2019 in Review
98 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Assembly Biosciences (ASMB) for Q3 2019, worth a combined $204M — down 29% from $286M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of ASMB and 11 opened new positions — a net loss of 8 holders — while 37 trimmed existing stakes and 32 added.
The largest buyer was Rock Springs Capital Management, adding an estimated $9.33M. The largest seller was OrbiMed, exiting entirely with an estimated $7.06M sold.
- 98 institutional investors held Assembly Biosciences (ASMB) as of Q3 2019, down from 106 in Q2 2019.
- Funds reported $204M of Assembly Biosciences stock for Q3 2019, down 29% quarter-over-quarter.
- 11 funds opened new Assembly Biosciences positions in Q3 2019 and 19 closed out, a net change of -8 holders.
- The largest Assembly Biosciences buyer in Q3 2019 was Rock Springs Capital Management, an estimated $9.33M added.
- The largest Assembly Biosciences seller in Q3 2019 was OrbiMed, an estimated $7.06M sold.
Based on aggregated 13F filings for Q3 2019.